Evidence mapPaperPMID 38843286Full record

ReviewCirculation research2024

The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future.

Douglas L Mann

Abstract readReviewHistorical Article
In one paragraph

Review in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. TIM-3 in Cardiovascular Disease.Current heart failure reports · 2026
    Review
  6. Review
  7. CXCL10 Regulates Pressure Overload-Induced Heart Failure.JACC. Basic to translational science · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Dysfunctional cardiomyocyte signalling and heart disease.Current opinion in cell biology · 2025
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Douglas L MannCardiovascular Division, Center for Cardiovascular Research, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-2516-0145

Funding

Apolipoprotein M: a novel regulator of myocardial AutophagyR01HL155344 · WASHINGTON UNIVERSITY · 2025 to 2025
$590k
BLRD VA I01 BX005065NHLBI NIH HHS R01 HL147968NHLBI NIH HHS R01 HL155344
6 · The paper itself

Abstract

Over the past 30 years, the field of cardioimmunology has moved from being dismissed as a field that was chasing an epiphenomenon of little biological consequence to a scientific discipline that is providing important new insights into the immunologic basis for hypertension, atherosclerosis, myocarditis, pericarditis, autoimmune heart disease, and heart failure. In this article, we will review the conceptual insights and technical breakthroughs that have allowed the field to move forward, as well as the clinical trials in the cardioimmunology space, to provide a historical context for the articles that will appear in the compendium that is focused on the interface between cardioimmunology, myocardial function, and disease.

Indexed as

Heart DiseasesAllergy and ImmunologyAnimalsCardiovascular DiseasesHistory, 20th CenturyHistory, 21st CenturyHumansatherosclerosisheart failurehypertensionmyocarditispericarditis

Identifiers

PMID38843286
PMCPMC11160976

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.